Clinical Trial Update: Study Evaluating TMI-005 in Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TMI-005 in active rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• TMI-005

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED